Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been given an average rating of “Moderate Buy” by the fourteen analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $44.40.

A number of equities research analysts have weighed in on the company. Wolfe Research initiated coverage on Olema Pharmaceuticals in a research report on Friday. They set a “peer perform” rating on the stock. Oppenheimer reiterated an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Stifel Nicolaus began coverage on Olema Pharmaceuticals in a research report on Wednesday, February 11th. They set a “buy” rating and a $48.00 price objective on the stock. Piper Sandler started coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. boosted their target price on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ:OLMA opened at $13.67 on Friday. The company’s fifty day moving average price is $21.63 and its 200-day moving average price is $18.97. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -7.35 and a beta of 1.92. Olema Pharmaceuticals has a one year low of $2.86 and a one year high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.95 and a quick ratio of 9.95.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. On average, equities research analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, insider Shawnte Mitchell sold 25,000 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the completion of the transaction, the insider owned 139,727 shares in the company, valued at approximately $4,014,356.71. The trade was a 41.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 217,311 shares of company stock valued at $5,965,254. 16.36% of the stock is owned by insiders.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC grew its stake in shares of Olema Pharmaceuticals by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after buying an additional 477 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Olema Pharmaceuticals by 8.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock valued at $325,000 after acquiring an additional 987 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after acquiring an additional 1,169 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares during the period. Finally, ProShare Advisors LLC grew its position in Olema Pharmaceuticals by 13.8% during the 4th quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after acquiring an additional 1,740 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.